Unique Biomarkers Identified for Use in Thyroid Cancer Follow-Up January 2017 | Researchers have identified two unique biomarkers that show promise for monitoring patients who have received treatment for papillary thyroid cancer (PTC), according to a study recently published in the new open access Journal of the Endocrine Society…
Explore highlights of current education across the Endocrine Society.
Selecting a Target in Refractory Cushing Disease
ENDO Session | No credit available
Maria Fleseriu, MD
What’s your best option? Use the latest information on medical therapies from clinical trials to treat your patients with persistent disease.
Evaluation and Management of Neuroendocrine Tumors
ENDO Session | No credit available
Faculty: Karel Pacak, MD; Wouter W. de Herder, MD; and Thomas M. O’Dorisio
Hear cases, learn strategies, and test yourself on the diagnosis, localization, and treatment of NETs.
Hormones and Cancer Digital Toolkit Patient Resource | No credit available
Reviewer: Richard J. Santen, MD
Interactive and downloadable resources and information for patients with questions about endocrine-related cancers.
Controversies in the Management of Low-Risk Differentiated Thyroid Cancer Endocrine Reviews | June 19, 2017 Megan R Haymart, Nazanene H Esfandiari, Michael T Stang, and Julia Ann Sosa
Controversy exists over optimal management of low-risk differentiated thyroid cancer. This controversy occurs in all aspects of management, including surgery, use of radioactive iodine for remnant ablation, thyroid hormone supplementation, and long-term surveillance…
Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer JCEM | March 28, 2017 Keisuke Enomoto, Xuguang Zhu, Sunmi Park, Li Zhao, Yuelin J. Zhu, Mark C. Willingham, Jun Qi, John A. Copland, Paul Meltzer, and Sheue-yann Cheng
Anaplastic thyroid cancer (ATC) is one of the most aggressive cancers in humans. Studies have shown that human ATC derives from complex and heterogeneous genetic changes, making effective treatment a major challenge…
Cancer Risks in Patients Treated with Growth Hormone in Childhood: The SAGhE European Cohort Study JCEM | February 10, 2017 Anthony J Swerdlow, Rosie Cooke, Dominique Beckers, Birgit Borgström, Gary Butler, Jean-Claude Carel, Stefano Cianfarani, Peter Clayton, Joël Coste, Annalisa Deodati, Emmanuel Ecosse, Ruth Gausche, Claudio Giacomozzi, Anita CS. Hokken-Koelega, Aysha J Khan, Wieland Kiess, Claudia E. Kuehni, Primus-E. Mullis, Roland Pfaffle, Lars Sävendahl, Grit Sommer, Muriel Thomas, Anders Tidblad, Sally Tollerfield, Liesbet Van Eycken, and Gladys RJ. Zandwijken
Context: Growth Hormone (GH) is prescribed for an increasing range of indications, but there has been concern that it might raise cancer risk. Published data are limited…
Treatment of Cushing's Syndrome JCEM | July 29, 2015 Lynnette K. Nieman, Beverly M. K. Biller, James W. Findling, M. Hassan Murad, John Newell-Price, Martin O. Savage, and Antoine Tabarin
Treatment of Cushing's syndrome is essential to reduce mortality and associated comorbidities. Effective treatment includes the normalization of cortisol levels or action. It also includes…
Diagnosis and Treatment of Pheochromocytoma and Paraganglioma JCEM | June 03, 2014 Jacques W. M. Lenders, Quan-Yang Duh, Graeme Eisenhofer, Anne-Paule Gimenez-Roqueplo, Stefan K. G. Grebe, Mohammad Hassan Murad, Mitsuhide Naruse, Karel Pacak, and William F. Young Jr
The Task Force recommends that initial biochemical testing for PPGLs should include measurements of plasma free or urinary fractionated metanephrines. Consideration should be given to preanalytical factors…
The Diagnosis of Cushing's Syndrome JCEM | January 14, 2009 Lynnette K. Nieman, Beverly M. K. Biller, James W. Findling, John Newell-Price, Martin O. Savage, Paul M. Stewart, and Victor M. Montori
After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with…
For additional meetings, visit the Endocrine Society’s Worldwide Endocrinology Calendar at endocrine.org/calendar.
Clinical Endocrinology Update & Endocrine Board Review Dates: September 23–27, 2017 Location: Chicago, Illinois, United States Sponsor: Endocrine Society
Whether you need the latest clinical information or you’re preparing to certify or recertify for the boards, Clinical Endocrinology Update (CEU) and Endocrine Board Review (EBR) have you covered.
ENDO Bridge Dates: October 19–22, 2017 Location: Antalya, Turkey Sponsor: Endocrine Society, the European Society of Endocrinology, and The Society of Endocrinology and Metabolism of Turkey
EndoBridge will provide a comprehensive update in the field of endocrinology for the clinical endocrinologist. The official language of the meeting is English, but simultaneous translation will be available in Russian, Arabic, and Turkish
ENDO 2018 Dates: March 17–20, 2018 Location: Chicago, Illinois, United States Sponsor: Endocrine Society
ENDO is the world’s largest event for presenting and obtaining the latest in endocrine science and medicine with an extensive program covering a broad array of topics, various networking opportunities, poster sessions, updates on new products and technologies at the ENDOExpo, and more.